Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 2:10:1506.
doi: 10.3389/fimmu.2019.01506. eCollection 2019.

New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update

Affiliations
Review

New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update

Giovanni Genovese et al. Front Immunol. .

Abstract

There are several lines of evidence indicating that the physiopathological bases of bullous pemphigoid (BP), the most common subepidermal autoimmune bullous disease, are hallmarked by the production of autoantibodies directed against the hemidesmosomal anchoring proteins BP180 and BP230. In contrast to the robustness of the latter assumption, the multifaceted complexity of upstream and downstream mechanisms implied in the pathogenesis of BP remains an area of intense speculation. So far, an imbalance between T regulatory cells and autoreactive T helper (Th) cells has been regarded as the main pathogenic factor triggering the autoimmune response in BP patients. However, the contributory role of signaling pathways fostering the B cell stimulation, such as Toll-like receptor activation, as well as that of ancillary inflammatory mechanisms responsible for blister formation, such as Th17 axis stimulation and the activation of the coagulation cascade, are still a matter of debate. In the same way, the pathomechanisms implied in the loss of dermal-epidermal adhesion secondary to autoantibodies binding are not fully understood. Herein, we review in detail the current concepts and controversies on the complex pathogenesis of BP, shedding light on the most recent theories emerging from the literature.

Keywords: autoantibodies; autoimmune blistering diseases; autoimmunity; bullous pemphigoid; pathogenesis; skin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative figure of the main pathogenic pathways implied in blister formation in patients with bullous pemphigoid.

References

    1. Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol. (2018) 54:26–51. 10.1007/s12016-017-8633-4 - DOI - PubMed
    1. Cozzani E, Gasparini G, Burlando M, Drago F, Parodi A. Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects. Autoimmun Rev. (2015) 14:438–45. 10.1016/j.autrev.2015.01.006 - DOI - PubMed
    1. Iwata H, Kitajima Y. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida. Exp Dermatol. (2013) 22:381–5. 10.1111/exd.12146 - DOI - PubMed
    1. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol. (1986) 136:1231–5. - PubMed
    1. Amagai M, Hashimoto T, Tajima S, Inokuchi Y, Shimizu N, Saito M, et al. . Partial cDNA cloning of the 230-kD mouse bullous pemphigoid antigen by use of a human monoclonal anti-basement membrane zone antibody. J Invest Dermatol. (1990) 95:252–9. 10.1111/1523-1747.ep12484863 - DOI - PubMed